Barclays raised the firm’s price target on Sarepta (SRPT) to $209 from $203 and keeps an Overweight rating on the shares. The company reported a big Q3 beat on both total and Elevidys revenue ...
Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00. Don't Miss our Black Friday Offers: Luke Sergott has ...
CAMBRIDGE, Mass., November 06, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback